12:09 PM EST - Optimi Health : Announced that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility. Optimi has received a Section 56 Exemption to the Controlled Drugs and Substances Act from Health Canada in order to carry out its own research at the premises of Calgary-based Bloom Psychedelic Therapy & Research Centre, with a focus on determining a safe and effective standardized microdose of psilocybin for mental health conditions such as anxiety and depression. Optimi Health
shares C.OPTI are trading up $0.03 at $0.33.
